Skip to main content
Clinical Trials/NL-OMON46302
NL-OMON46302
Completed
Not Applicable

Platelet reactivity, inflammation and endothelial dysfunction during and after exacerbation in chronic obstructive pulmonary disease (COPD) patients - IMPROVE study

Gelre Ziekenhuizen0 sites76 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Gelre Ziekenhuizen
Enrollment
76
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Acute exacerbation of COPD, defined as an as an acute worsening of respiratory symptoms that results in additional therapy (COPD Gold 2018\)
  • \* \>40 years oud
  • \* Moderate to severe (\>Gold 2\) airflow limitation detected by spirometry (FEV1/FVC ratio \< 70%, FEV1 \< 80%) and clinical diagnosis of COPD confirmed by a pulmonologist.
  • \* Current or former smoker, with \*10 pack years of smoking

Exclusion Criteria

  • \* Suspected or proven alternative diagnosis for the acute deterioration in symptoms such as pneumonia, pulmonary embolism or heart failure
  • \* Use of anti\-coagulants, aspirin or other platelet function inhibitors
  • \* Use of statins or ACE inhibitors
  • \* Concomitant diagnosis of asthma or other respiratory disease
  • \* Diagnosis of hepatic and/or renal failure
  • \* Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, systemic lupus erythematous (SLE), diabetes mellitus (DM)
  • \* Malignancies (excluding basal cell carcinoma of the skin)

Outcomes

Primary Outcomes

Not specified

Similar Trials